肝炎治療の世界市場:病型別(A型肝炎、B型肝炎、C型肝炎)、地域別、セグメント予測

◆英語タイトル:Hepatitis Therapeutics Market Size, Share, And Trend Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025
◆商品コード:GVIEW805057
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2018年4月23日
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Pharmaceuticals
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥874,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,094,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、肝炎治療の世界市場について調査・分析し、肝炎治療の世界市場動向、肝炎治療の世界市場規模、市場予測、セグメント別肝炎治療市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc. Few factors that are expected to drive the market over the forecast period include rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.
Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Further Key Findings From the Report Suggest:

• Owing to high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2016

• In 2016, North American region accounted for majority of revenue share of 42.9% owing to high patient awareness levels and the presence of advanced healthcare infrastructure

• However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period owing to rapidly increasing healthcare expenditure

• Key players include Gilead, Johnson & Johnson, Merck & Co. Inc., Bristol-Myers Squibb Company, and AbbVie Inc.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Hepatitis Therapeutics Market Variables, Trends & Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis – Porter’s
3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015
Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million)
4.2. Hepatitis A
4.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.3. Hepatitis B
4.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.4. Hepatitis C
4.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.5. Others
4.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
Chapter 5. Hepatitis Therapeutics Market: Regional Outlook, By Disease Type
5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million)
5.2. North America
5.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.2.2. U.S.
5.2.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.2.3. Canada
5.2.3.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3. Europe
5.3.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3.2. Germany
5.3.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3.3. UK
5.3.3.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4.2. China
5.4.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4.3. Japan
5.4.3.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5. Latin America
5.5.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5.2. Brazil
5.5.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5.3. Mexico
5.5.3.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.6. Middle East & Africa
5.6.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.6.2. South Africa
5.6.2.1. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
Chapter 6. Competitive Landscape
6.1. Gilead Lifesciences
6.1.1. Company overview
6.1.2. Financial performance
6.1.3. Product benchmarking
6.1.4. Strategic initiatives
6.2. Bristol-Myers Squibb Co
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Biocon
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. AbbVie
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. Merck & Co., Inc.,
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. Johnson & Johnson
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives

List of Tables

TABLE 1 Hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 2 North America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 3 U.S. hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 4 Canada hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 5 Europe hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 6 Germany hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 7 UK hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 8 Asia Pacific hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 9 China hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 10 Japan hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 11 Latin America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 12 Brazil hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 13 Mexico hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 14 Middle East & Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 15 South Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Hepatitis therapeutics market, Heat Map Analysis
FIG. 13 Hepatitis therapeutics market product outlook key takeaways
FIG. 14 Hepatitis therapeutics market: Disease type movement analysis
FIG. 15 Hepatitis A market, 2014 - 2025 (USD Million)
FIG. 16 Hepatitis B market, 2014 - 2025 (USD Million)
FIG. 17 Hepatitis C market, 2014 - 2025 (USD Million)
FIG. 18 Other hepatitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 19 Regional outlook, 2015 & 2024
FIG. 20 North America hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 21 U.S. hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 Canada hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Europe hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Germany hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 UK hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 Asia Pacific hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 China hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 Japan hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 Latin America hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 Brazil hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 Mexico hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 MEA hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 South Africa hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肝炎治療の世界市場:病型別(A型肝炎、B型肝炎、C型肝炎)、地域別、セグメント予測(Hepatitis Therapeutics Market Size, Share, And Trend Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆